RESMED CDI
Weekly Wrap: Market steps back from the brink with a rise
Weekly Wrap: Late pullback slams gold shares
ASX slips 0.7% as late pullback drags gold shares lower on Fed chair speculation; bullion drops ~5% amid rate-hike fears.
ResMed delivers double-digit EPS growth on increasing demand for sleep apnoea devices
ResMed (ASX: RMD) has reported double-digit earnings per share (EPS) growth for the three months to March on the back of increasing market demand for its best-in-class sleep apnoea products and software solutions. The company’s revenue for the period increased by 8% to US$1.3 billion (up 9% on a constant currency basis), while income from […]
ResMed shares hit as Eli Lilly’s weight loss drug demonstrates sleep apnoea benefits
Medical device maker ResMed (ASX: RMD) saw its shares tumble more than 13% after pharmaceutical rival Eli Lilly announced that its weight-loss drug Zepbound (tirzepatide) could also help resolve sleep apnoea in some patients. California-based ResMed is a giant in the sleep apnoea space, manufacturing face masks, nasal devices and continuous positive airway pressure (PAP) […]